Welcome to our dedicated page for Rapport Therapeutics SEC filings (Ticker: RAPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. is asking stockholders to vote at its June 10, 2026 virtual annual meeting on electing three Class II directors (James Healy, Robert Perez and Raymond Sanchez) and ratifying PricewaterhouseCoopers LLP as independent auditor for 2026.
Stockholders of record at the close of business on April 14, 2026, when 47,807,623 common shares were outstanding, are entitled to vote online or by proxy. The company describes a staggered nine‑member board, committee structure and independence determinations, along with its governance policies on insider trading, Rule 10b5‑1 plans and compensation recovery.
The proxy details 2025 compensation for key executives, including CEO Abraham Ceesay with total compensation of $6,265,174, CFO Troy Ignelzi with $2,506,139 and Chief Medical Officer Jeffrey Sevigny with $3,023,942, combining salary, performance-based bonuses and equity awards.
Rapport Therapeutics, Inc. insider entities affiliated with Third Rock Ventures reported an open‑market sale of 426,005 shares of common stock at a weighted average price of $40.317 per share. After the sale, one reporting holder retained 6,709,228 shares directly, while another related fund held 969,218 shares indirectly. The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan dated November 21, 2025.
Rapport Therapeutics Chief Development Officer sells shares under pre-planned program. Yeleswaram Krishnaswamy completed an open-market sale of 20,225 shares of Rapport Therapeutics common stock at a weighted average price of $39.9923 per share. After the sale, he directly holds 246,426 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was pre-scheduled rather than a discretionary trade.
Rapport Therapeutics reported follow-up data from its Phase 2a trial of RAP-219 in drug‑resistant focal onset seizures, showing sustained efficacy after dosing stopped. In weeks 9‑12, patients saw an 80% median reduction in long episodes and 90% median reduction in clinical seizures versus baseline, and in weeks 13‑16, reductions were 68% and 59%, respectively. Over the full 16‑week treatment plus follow‑up period, median reductions were 69% for long episodes and 68% for clinical seizures, with seizure freedom in 12% of patients.
RAP‑219 is now estimated to have an approximately 22‑day half‑life, with receptor occupancy above 60% throughout follow‑up, and was generally well tolerated, including only mild treatment‑related adverse events in the follow‑up period. Rapport plans two pivotal Phase 3 trials in focal onset seizures starting in the second quarter of 2026, a Phase 3 trial in primary generalized tonic‑clonic seizures in the first half of 2027, and a Phase 2 trial in bipolar mania with topline results expected in the first half of 2027. The company is also advancing a long‑acting injectable formulation and other neurology programs, supported by a cash balance of $490.5 million as of December 31, 2025 and an expected cash runway into the second half of 2029.
Morgan Stanley Smith Barney LLC reported Form 144 notice of proposed sales of Common stock for an identified holder under 10b5-1 plans. The excerpt lists multiple sale dates and share amounts, including 10,200 shares on 04/14/2026 and 9,165 shares on 04/13/2026. These are routine brokered dispositions under pre-arranged plans.
Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares of common stock in open-market transactions. The sales occurred on April 10, 13, and 14, 2026 at weighted average prices of $34.98, $34.97, and $35.08 per share, respectively. According to the filing, these trades were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following the last sale, he continues to directly own 266,651 shares of Rapport Therapeutics common stock.
Morgan Stanley Smith Barney LLC filed a Form 144 notice relating to the proposed sale of Common shares connected with an affiliate account. The filing lists three 10b5-1 sales by KRISHNASWAMY: 10,115 shares on 03/25/2026, 360 shares on 04/08/2026, and 500 shares on 04/10/2026, with dollar amounts shown alongside each transaction. The cover block includes a figure of 47,792,943 shares as of 04/13/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 disclosing proposed sales of 500 shares of Common Stock by a holder and recent 10b5-1 dispositions by Krishnaswamy. The filing lists 10b5-1 sales of 360 shares for $12,564.00 (04/08/2026) and 10,115 shares for $303,354.24 (03/25/2026).